Variantyx Licenses IBM Technologies That Leverage AI for Somatic Analysis
Variantyx, the leader in high complexity hereditary disease testing, today announced that it has entered into a licensing agreement with IBM for technologies that leverage artificial intelligence for somatic analysis from which Variantyx intends to develop comprehensive tumor diagnostic solutions.
“Variantyx’s proprietary whole genome sequencing (WGS)-based methodology has transformed genetic testing and personalized medicine for pediatric and adult neurological disorders and rare, undiagnosed diseases,” said Haim Neerman, CEO of Variantyx. “This license agreement will accelerate development of a similarly transformative, cancer diagnostic solution.”
“We are pleased to support Variantyx as they work to advance the use of genomics to help scale precision medicine and meet the growing needs of personalized care,” said Ajay Royyuru, Vice President, Healthcare & Life Sciences Research, IBM.